NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,222.86 mln
Float73.16 mln
Earnings Date07/30/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.6
Likely manipulated
1-Year Forecast
90.60
Strong upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
-2.19
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
PTC Therapeutics is a US-based drug development company focused on creating treatments for rare and serious conditions that affect both children and adults around the world. The company sells several approved medicines targeting diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain nervous system disorders, while also advancing a pipeline of new treatments for conditions like Huntington's disease and Friedreich's ataxia. PTC works alongside a number of notable partners, including Roche and Novartis, to develop and bring these therapies to patients. Founded in 1998 and headquartered in Warren, New Jersey, the company distributes its products through third-party partners across multiple markets.
